Original research: Telmisartan plus amlodipine in patients with moderate or severe hypertension: Results from a subgroup analysis of a randomized, placebo-controlled, parallel-group, 4 x 4 factorial study

Postgraduate Medicine

Volumn 121, Issue 2, 2009, Pages 5-14

  Littlejohn III, Thomas W ^a   Majul, Claudio R ^b   Olvera, R ^c   Seeber, Mary ^d   Kobe, Maureen ^e   Guthrie, Robert ^f   Oigman, Wille ^g  

^a Piedmont Medical Research Associates   (United States)

^b Hospital Santojanni Buenos Aires   (Argentina)

^c Clínica de Estudios Médicos SC   (Mexico)

^d Medi Clinic Heart Hospital   (South Africa)

^e BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Amlodipine; Factorial design; Moderate or severe hypertension; Telmisartan

Indexed keywords

AMLODIPINE; AMLODIPINE BESYLATE; TELMISARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; FACTORIAL ANALYSIS; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PERIPHERAL EDEMA; RANDOMIZED CONTROLLED TRIAL; SYNCOPE; SYSTOLIC BLOOD PRESSURE; ANALYSIS OF VARIANCE; BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG EFFECT; DRUG TOXICITY; MIDDLE AGED; MULTICENTER STUDY;

AMLODIPINE; ANALYSIS OF VARIANCE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DRUG TOXICITY; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED;

EID: 64849092873     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2009.03.1972     Document Type: Article

References (29)

1. Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007;49(1):69-75.
2. Cheung BM, Ong KL, Man YB, Lam KS, Lau CP. Prevalence, awareness, treatment, and control of hypertension: United States National Health and Nutrition Examination Survey 2001-2002. J Clin Hypertens (Greenwich). 2006;8(2):93-98.
3. Fang J, Alderman MH, Keenan NL, Ayala C, Croft JB. Hypertension control at physicians' offices in the United States. Am J Hypertens. 2008;21(2):136-142.
4. Ezzati M, Oza S, Danaei G, Murray CJ. Trends and cardiovascular mortality effects of state-level blood pressure and uncontrolled hypertension in the United States. Circulation. 2008;117(7):905-914.
5. Chobanian AV, Bakris GL, Black HR, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA. 2003;289(19):2560-2572.
6. Smith DH. Fixed-dose combination antihypertensives and reduction in target organ damage: are they all the same? Am J Cardiovasc Drugs. 2007;7(6):413-422. (Pubitemid 350256049)
7. Düsing R. Overcoming barriers to effective blood pressure control in patients with hypertension. Curr Med Res Opin. 2006;22(8):1545-1553. (Pubitemid 44297433)
8. Nilsson PM. Optimising the pharmacologic treatment of hypertension: BP control and target organ protection. Am J Cardiovasc Drugs. 2006;6(5):287-295. (Pubitemid 44754679)
9. Tedesco MA, Natale F, Calabrò R. Effects of monotherapy and combination therapy on blood pressure control and target organ damage: a randomized prospective intervention study in a large population of hypertensive patients. J Clin Hypertens. 2006;8(9):634-641.
10. Saito F, Fujita H, Takahashi A, et al. Renoprotective effect and cost-effectiveness of using benidipine, a calcium channel blocker, to lower the dose of angiotensin receptor blocker in hypertensive patients with albuminuria. Hypertens Res. 2007;30(1):39-47. (Pubitemid 46259797)
11. Egan BM. Combination therapy with an angiotensin-converting enzyme inhihilor and a calcium channel blocker. J Clin Hypertens. 2007;9(10):783-789.
12. Weber MA, Bakris GL, Dahlöf B, et al. Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk. Blood Press. 2007;16(1):13-19. (Pubitemid 46672249)
13. Ishimitsu T, Kobayashi T, Honda T, et al. Protective effects of an angiotensin II receptor blocker and a long-acting calcium channel blocker against cardiovascular organ injuries in hypertensive patients. Hypertens Res. 2005;28(4):351-359. (Pubitemid 40895058)
14. Benndorf RA, Appel D, Maas R, Schwedhelm E, Wenzel UO, Böger RH. Telmisartan improves endothelial function in patients with essential hypertension. J Cardiovasc Pharmacol. 2007;50(4):367-371.
15. Poldermans D, Glazes R, Kargiannis S, et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther. 2007;29(2):279-289. (Pubitemid 46661857)
16. Croxtall JD, Keating GM. Irbesartan/hydrochlorothiazide: in moderate to severe hypertension. Drugs. 2008;68(10):1465-1472.
17. Volpe M, Brommer P, Haag U, Miele C. Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig. 2009;29(1):11-25.
18. Sharma AM, Davidson J, Koval S, Lacourcière Y. Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study. Cardiovasc Diabetol. 2007;6:28. (Pubitemid 350142923)
19. White WB, Murwin D, Chrysant SG, Koval SE, Davidai G, Guthrie R. Effects of the angiotensin II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial. Blood Press Monit. 2008;13(1):21-27.
20. Sharma A, Bagchi A, Kinagi SB, Sharma YK, Baliga VP, Bollmall C. Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension. Clin Ther. 2007;29(12):2667-2676.
21. Fogari R, Derosa G, Zoppi A. Effect of telmisartan-amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria. Am J Hypertens. 2007;20(4):417-422. (Pubitemid 46441757)
22. Littlejohn III T, Majul CR, Olvera R, et al. Results of treatment with telmisartan-amlodipine in hypertensive patients. J Clin Hypertens. In press.
23. American Society of Hypertension. Recommendations for routine blood pressure measurement by indirect cuff sphygmomanometry. Am J Hypertens. 1992;5(4 pt 1):207-209.
24. McInnes GT. Lowering blood pressure for cardiovascular risk reduction. J Hypertens Suppl. 2005;23(1):S3-S8. (Pubitemid 43175103)
25. Preston RA, Baltodano NM, Cienki J, Materson BJ. Clinical presentation and management of patients with uncontrolled, severe hypertension: results from a public teaching hospital. J Hum Hypertens. 1999;13(4):249-255. (Pubitemid 29187006)
26. Norris K, Neutel JM. Emerging insights in the first-step use of antihypertensive combination therapy. J Clin Hypertens (Greenwich). 2007;9(suppl 5):5-14.
27. Julius S, Kjeldsen SE, Weber M, et al; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022-2031. (Pubitemid 38781102)
28. Fogari R, Zoppi A, Derosa G, et al. Effect of valsartan addition lo amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens. 2007;21(3):220-224. (Pubitemid 46267738)
29. Chrysant SG, Melino M, Karki S, Lee J, Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther. 2008;30(4):587-604.